Trial · NCT00424294
Results by group220
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 220
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Percentage of Participants Achieving American College of Rheumatology 20% (ACR20) Response at Week 12 | Placebo and Celecoxib | 31.43 | percentage of participants | ||
| Percentage of Participants Achieving American College of Rheumatology 20% (ACR20) Response at Week 12 | CP-195543 and Celecoxib | 35.29 | percentage of participants | ||
| Percentage of Participants Achieving American College of Rheumatology 20% (ACR20) Response at Week 1, 2, 4 and 8 | Placebo and Celecoxib | Week 1 | 31.43 | percentage of participants | |
| Percentage of Participants Achieving American College of Rheumatology 20% (ACR20) Response at Week 1, 2, 4 and 8 | CP-195543 and Celecoxib | Week 1 | 23.53 | percentage of participants | |
| Percentage of Participants Achieving American College of Rheumatology 20% (ACR20) Response at Week 1, 2, 4 and 8 | Placebo and Celecoxib | Week 2 | 28.57 | percentage of participants | |
| Percentage of Participants Achieving American College of Rheumatology 20% (ACR20) Response at Week 1, 2, 4 and 8 | CP-195543 and Celecoxib | Week 2 | 35.29 | percentage of participants | |
| Percentage of Participants Achieving American College of Rheumatology 20% (ACR20) Response at Week 1, 2, 4 and 8 | Placebo and Celecoxib | Week 4 | 28.57 | percentage of participants | |
| Percentage of Participants Achieving American College of Rheumatology 20% (ACR20) Response at Week 1, 2, 4 and 8 | CP-195543 and Celecoxib | Week 4 | 41.18 | percentage of participants | |
| Percentage of Participants Achieving American College of Rheumatology 20% (ACR20) Response at Week 1, 2, 4 and 8 | Placebo and Celecoxib | Week 8 | 25.71 | percentage of participants | |
| Percentage of Participants Achieving American College of Rheumatology 20% (ACR20) Response at Week 1, 2, 4 and 8 | CP-195543 and Celecoxib | Week 8 | 38.24 | percentage of participants | |
| Percentage of Participants Achieving American College of Rheumatology 50% (ACR50) Response | Placebo and Celecoxib | Week 1 | 0.0 | percentage of participants | |
| Percentage of Participants Achieving American College of Rheumatology 50% (ACR50) Response | CP-195543 and Celecoxib | Week 1 | 0.0 | percentage of participants | |
| Percentage of Participants Achieving American College of Rheumatology 50% (ACR50) Response | Placebo and Celecoxib | Week 2 | 0.0 | percentage of participants | |
| Percentage of Participants Achieving American College of Rheumatology 50% (ACR50) Response | CP-195543 and Celecoxib | Week 2 | 0.0 | percentage of participants | |
| Percentage of Participants Achieving American College of Rheumatology 50% (ACR50) Response | Placebo and Celecoxib | Week 4 | 8.57 | percentage of participants | |
| Percentage of Participants Achieving American College of Rheumatology 50% (ACR50) Response | CP-195543 and Celecoxib | Week 4 | 2.94 | percentage of participants | |
| Percentage of Participants Achieving American College of Rheumatology 50% (ACR50) Response | Placebo and Celecoxib | Week 8 | 5.71 | percentage of participants | |
| Percentage of Participants Achieving American College of Rheumatology 50% (ACR50) Response | CP-195543 and Celecoxib | Week 8 | 11.76 | percentage of participants | |
| Percentage of Participants Achieving American College of Rheumatology 50% (ACR50) Response | Placebo and Celecoxib | Week 12 | 8.57 | percentage of participants | |
| Percentage of Participants Achieving American College of Rheumatology 50% (ACR50) Response | CP-195543 and Celecoxib | Week 12 | 14.71 | percentage of participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT00424294/results